FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS(TM) (raltegravir), Merck & Co., Inc.'s Investigational Oral Integrase Inhibitor, for Treatment of HIV

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend accelerated FDA approval of ISENTRESS™ (raltegravir) in combination with other antiretroviral therapy (ART) for the treatment of HIV infection in treatment-experienced patients with ongoing viral replication despite existing therapy.